Avicenna.AI

ai SAS, founded in 2018 in La Ciotat, France, specializes in AI-driven diagnostic tools for emergency radiology.AI specializes in delivering advanced artificial intelligence (AI) solutions designed specifically for emergency radiology and the detection of incidental findings in CT scans. The company's primary product offerings include CINA-ICH, which identifies suspected intracranial hemorrhages, CINA-LVO for detecting large vessel occlusions in ischemic strokes, and CINA-ASPECTS, an AI-based quantification tool that assesses acute ischemic strokes using the Alberta Stroke Program Early CT Score. Additional solutions encompass CINA-PE for pulmonary embolism detection, CINA-AD for aortic dissection identification, and CINA-iPE, which detects lung blood clots in patients undergoing imaging for other conditions. These tools significantly enhance the speed and accuracy of diagnoses, thereby allowing medical professionals to focus on urgent cases.AI operates on a subscription-based revenue model, where healthcare institutions and radiology departments pay for access to its suite of AI tools.10. Transactions typically involve annual or multi-year agreements that allow users to integrate these advanced tools into their existing workflows, ensuring seamless access to features such as automated detection alerts and prioritization of critical cases. The company aims to introduce additional AI products and target expansion into new geographic regions, although specific markets and timelines have not been detailed at this time.AI's capabilities in medical diagnostics.

1. Series A

   Mar 9, 2023

   Amount

   $3.2M

   Investors

   Locked